Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Objectives To assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).

Methods In this 24-week multicentre, placebo-controlled, double-blind study, the patients were randomised in a 2:2:1 ratio to receive subcutaneously administered OKZ 64 mg once every 2 weeks (q2w), OKZ 64 mg once every 4 weeks (q4w) or PBO plus methotrexate. At week 16, the patients on PBO were randomised to receive either OKZ regime. The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20% (ACR20) response at week 12. Disease Activity Score 28-joint count C-reactive protein (DAS28 (CRP)) <3.2 at week 12 was the major secondary efficacy endpoint. Safety and immunogenicity were assessed.

Results In 368 patients randomised, ACR20 response rates were 60.9% in OKZ q2w, 59.6% in OKZ q4w and 40.6% in PBO (p<0.01 for both comparisons). Achievement of DAS28 (CRP) <3.2 was significantly different, favouring the OKZ arms. Improvements in efficacy and patientreported outcomes were maintained throughout 24 weeks and were noted after week 16 in patients who switched from PBO.Dose-related treatment-emergent serious adverse events were 7% in OKZ q2w, 3.2% in OKZ q4w and none in the PBO group.

Conclusions Direct inhibition of IL-6 with OKZ resulted in significant improvements in the signs and symptoms of rheumatoid arthritis compared with PBO in TNFi-IR patients with a similar safety profile as observed for monoclonal antibodies to the IL-6 receptor.

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023-38.

2. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1-26.

3. Smolen JS, Landewй RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685-99.

4. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360-72.

5. Johnson KJ, Sanchez HN, Schoenbrunner N. Defining response to TNF-inhibitors In rheumatoid arthritis: the negative impact of antiTNF cycling and the need for a personalized medicine approach to identify primary nonresponders. Clin Rheumatol 2019; 38:2967-76.

6. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2021;73:1108-23.

7. Hunter CA, Jones SA. Il-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448-57.

8. Genovese MC, van der Heijde D, Lin Y, et al. Long-Term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open 2019;5:e000887.

9. Hushaw LL, Sawaqed R, Sweis G, et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010;6:143-52.

10. Kenney B. Janssen receives complete response letter from U.S. FDA for sirukumab biologics license application, 2017. Available: https://www.jnj.com/media-center/pressreleases/janssen-receives-complete-responseletter-from-us-fda-for-sirukumabbiologicslicense-application [Accessed 1 Jul 2022].

11. Shaw S, Bourne T, Meier C, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs 2014; 6:774-82.

12. Genovese MC, Fleischmann R, Furst D, et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann Rheum Dis 2014;73:1607-15.

13. Takeuchi T, Tanaka Y, Yamanaka H, et al. Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: results from a randomized phase II trial. Mod Rheumatol 2016;26:15-23.

14. Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2022; 387:715-26.

15. Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomized controlled phase III study. Ann Rheum Dis2022;81:469-79.

16. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken, NJ, USA: John Wiley & Sons, Inc, 1987.

17. Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol 2017; 69:277-90.

18. Fleischmann R, Pangan AL, Song I-H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 2019;71: 1788-800.

19. Aletaha D, Strand V, Smolen JS, et al. Treatment-Related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis 2008;67:238-43.

20. Smolen JS, Aletaha D, Grisar JC, et al. Estimation of a numerical value for jointdamage-related physical disability in rheumatoid arthritis clinical trials. Ann Rheum Dis 2010; 69:1058-64.

21. Feist E, Chohan S, Fatenejad S, et al. P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study. Rheumatology 2021;60:keab247.126.

22. Hunter CA, Jones SA. Il-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448-57.

23. Robak T, Gladalska A, Stepie H, et al. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm 1998; 7:347-53.

24. Scheller J, Garbers C, Rose-John S. Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities. Semin Immunol 2014;26:2-12.

25. Dougados M, van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.

26. Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 2021;80:848-58.

27. Kerschbaumer A, Rivai ZI, Smolen JS, et al. OP0127 CONFOUNDING EFFECTS OF CONTINUED METHOTREXATE IN PLACEBO ARMS (PLC) OF RHEUMATOID ARTHRITIS (RA) CLINICAL TRIALS – A POST-HOC ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS (RCTS). Ann Rheum Dis 2021;80:71-2.

28. Kerschbaumer A, Rivai ZI, Smolen JS. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. Ann Rheum Dis 2022. [Epub ahead of print: 20 Jun 2022].

29. Fleischmann RM, Feist E, Fatenejad S. Efficacy and safety of Olokizumab in a phase III trial of patients with moderately to severely active rheumatoid arthritis inadequately controlled by TNF-αinhibitor therapy. Arthritis Rheumatol 2021;73 https://acrabstracts.org/abstract/efficacyand-safety-of-olokizumab-in-a-phase-iiitrialof-patients-with-moderately-to-severelyactive-rheumatoid-arthritis-inadequatelycontrolled-by-tnf-%ce%b1-inhibitor-therapy/

30. Feist E, Fatenejad S, Grishin S, et al. P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy. Rheumatology 2021;60: keab247.132.